Endocrine Society GUIDELINES Bundle (free trial)

Lipid Management in Endocrine Disorders

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1356565

Contents of this Issue

Navigation

Page 18 of 21

19 LDL-C reduction Major drug interactions 15–20 % Cyclosporine, fenofibrate, fibrates, cholestyramine 56–61% on background of statin None known 63–71% on a background of a statin; 41–45% on background of statin + ezetimibe None known 12%–25% When given concomitantly with warfarin, thiazide diuretics, thyroxine, estrogens and progestins, tetracycline, phenobarbital, penicillin G, acetaminophen, phosphate supplements 15–18% When given concomitantly with oral contraceptives, levothyroxine, warfarin, glimepiride, glipizide, phenytoin –18% on a background of a statin Limit simvastatin to 20 mg, limit pravastatin to 40 mg, cyclosporine From prescribing information for Daiichi Sankyo Inc. 2020, Ohm Laboratories Inc. 2020, Amgen Inc. 2017, Sanofi-Aventis U.S. LLC 2018, Eon Labs 2020, Esperion erapeautics 2020. All medications are to be used as adjunct to diet and exercise.

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Lipid Management in Endocrine Disorders